Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigette Ma

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|October 17, 2022
Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers - current evidence and future directionsRachel C T Lam, David Johnson, Gigi Lam, et al.
Frontiers in Oncology|September 12, 2025
<i>ISG15</i> mRNA transcript level in circulating leucocytes prognostic of overall survival in hepatocellular carcinoma patients and correlated with quality of life disturbances involved in anorexia-cachexiaLeung Li, Nelson L S Tang, Frankie Mo, et al.
Investigational New Drugs|June 19, 2015
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 doseKarthik Venkatakrishnan, Tae Min Kim, Chia-Chi Lin, et al.
Investigational New Drugs|September 14, 2007
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsBrigette Ma, Boon Cher Goh, Eng Huat Tan, et al.
Radiology|October 16, 2013
Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolizationSimon Chun Ho Yu, Joyce Wai Yi Hui, Edwin Pun Hui, et al.
Journal of the National Cancer Institute|March 27, 2019
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of ImmunotherapyQuynh Thu Le, A Dimitrios Colevas, Brian O'Sullivan, et al.
Cancer Chemotherapy and Pharmacology|September 1, 2007
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacyBrigette Ma, Edwin P Hui, Ann King, et al.
Clinical Colorectal Cancer|July 1, 2018
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International RegistryMatthew Burge, Christine Semira, Belinda Lee, et al.
Cancer Science|November 29, 2019
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsYung-Jue Bang, Wu-Chou Su, Martin Schuler, et al.
Molecular Cancer Research : MCR|November 5, 2013
The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylationGigi C G Choi, Jisheng Li, Yajun Wang, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|October 17, 2022
Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers - current evidence and future directionsRachel C T Lam, David Johnson, Gigi Lam, et al.
Frontiers in Oncology|September 12, 2025
<i>ISG15</i> mRNA transcript level in circulating leucocytes prognostic of overall survival in hepatocellular carcinoma patients and correlated with quality of life disturbances involved in anorexia-cachexiaLeung Li, Nelson L S Tang, Frankie Mo, et al.
Investigational New Drugs|June 19, 2015
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 doseKarthik Venkatakrishnan, Tae Min Kim, Chia-Chi Lin, et al.
Investigational New Drugs|September 14, 2007
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsBrigette Ma, Boon Cher Goh, Eng Huat Tan, et al.
Radiology|October 16, 2013
Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolizationSimon Chun Ho Yu, Joyce Wai Yi Hui, Edwin Pun Hui, et al.
Journal of the National Cancer Institute|March 27, 2019
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of ImmunotherapyQuynh Thu Le, A Dimitrios Colevas, Brian O'Sullivan, et al.
Cancer Chemotherapy and Pharmacology|September 1, 2007
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacyBrigette Ma, Edwin P Hui, Ann King, et al.
Clinical Colorectal Cancer|July 1, 2018
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International RegistryMatthew Burge, Christine Semira, Belinda Lee, et al.
Cancer Science|November 29, 2019
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsYung-Jue Bang, Wu-Chou Su, Martin Schuler, et al.
Molecular Cancer Research : MCR|November 5, 2013
The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylationGigi C G Choi, Jisheng Li, Yajun Wang, et al.
Pageof 5